<DOC>
	<DOCNO>NCT01980940</DOCNO>
	<brief_summary>Study Part 1 design ass plasma pharmacokinetics etoricoxib ( ETOR ) 4 % dimethyl sulfoxide ( DMSO ) propylene glycol ( PG ) formulation , 2 different dos , upon single-dose topical administration knee osteoarthritis participant . Study Part 2 design evaluate efficacy topical etoricoxib vs. placebo treatment osteoarthritis knee . The primary hypothesis topical etoricoxib effective placebo treatment osteoarthritis knee 2 week treatment assess time-weighted average change baseline Western Ontario McMaster Universities Arthritis Index ( WOMAC ) Visual Analogue ( VA ) 3.0 pain subscale .</brief_summary>
	<brief_title>The Single Dose Pharmacokinetics Two Proof Efficacy One New Etoricoxib Gel Formulation Participants With Osteoarthritis ( MK-0663-168 )</brief_title>
	<detailed_description>Part I study consist single-dose , open-label , randomize , four-way cross study topical administration etoricoxib gel knee osteoarthritis participant . The washout successive dose administration least one week . Part 2 study consist double-blind , randomize , placebo-controlled , parallel group , multiple dose , twice daily topical administration etoricoxib placebo gel knee osteoarthritis participant period two week .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Etoricoxib</mesh_term>
	<mesh_term>Dimethyl Sulfoxide</mesh_term>
	<criteria>Inclusion Criteria Has diagnosis osteoarthritis knee ( tibiofemoral joint ) &gt; 6 month base clinical radiographic criterion ; Has diagnosis American Rheumatology Association ( ARA ) functional Class I , II , III ; The knee designate `` study joint '' must participant 's primary source pain/disability low extremity . If knee affect , painful joint select evaluation inclusion clinical response ; Female participant childbearing potential must demonstrate serum beta human chorionic gonadotropin ( βhCG ) level consistent nongravid state screen visit urine βhCG Day 1 prior first dose agree use adequate oral barrier contraception abstain sexual contact least 7 day prior treatment continue treatment period discontinuation visit ; Willing limit alcohol intake ( beer 8 ounce , wine 4 ounce , liquor 1 ounce ) 14 drink week ( 2 day ) avoid unaccustomed strenuous physical activity ( e.g. , unaccustomed weight lifting , initiation physical therapy ) duration study ; Judged general good health exception osteoarthritis base medical history , physical examination , routine laboratory test . For Part 2 , participant regular user nonsteroidal antiinflammatory drug ( NSAIDs ) include coxibs he/she must report history positive therapeutic benefit osteoarthritis knee NSAID/coxibs past ; For Part 2 , participant must take single NSAID regular basis prescription strength least 30 day prior study screen ( `` regular basis '' define least 25 previous 30 day ) treatment symptom osteoarthritis . Has concurrent medical/arthritic disease ; History acute ligamentous meniscal injury study joint within previous 2 year arthroscopy affect knee within 6 month prior study entry ; Is candidate imminent joint replacement ; Has clinical laboratory evidence significant renal , gastrointestinal , pulmonary , hepatic , endocrine , neurological ( apart migraine ) , systemic disease opinion investigator contraindicates use etoricoxib ; Has congestive heart failure symptom occur rest minimal activity ; Has unstable angina occur rest minimal activity ; Has uncontrolled hypertension ( sit diastolic blood pressure &gt; 95 mm Hg , sit systolic blood pressure &gt; 165 mm Hg ) ; Has history stroke transient ischemic attack ( TIA ) within previous 6 month ; Has history hepatitis/hepatic disease active within previous 2 year ; Has history neoplastic disease ; Is currently user ( include `` recreational use '' ) illicit drug , history drug alcohol abuse within past 5 year ; Is allergic hypersensitivity aspirin , ibuprofen , rofecoxib , celecoxib , valdecoxib , NSAIDs , acetaminophen , sulfa drug ; Has use intravenous , intramuscular , oral corticosteroid within 1 month study entry ; Has use glucosamine and/or chondroitin sulfate &lt; 6 month prior study start ; Has use intraarticular steroid , HYALGAN™ ( sodium hyaluronate , Sanofi Pharmaceuticals ) , SYNVISC™ ( hylan GF 20 , WyethAyerst Pharmaceuticals ) study joint within 3 month entry study intraarticular steroid , HYALGAN™ , SYNVISC™ joint within 1 month study entry ; Has use topical , oral systemic analgesic medication within 2 week study entry duration study ; Requires treatment warfarin , heparin , highdose aspirin ( &gt; 325 mg ) , digoxin ; Has use Arcoxia® within 2 week study entry .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>